Article preview reprinted from Start-Up - December 2008
There's been a buzz around Sequenom's prenatal diagnostic technology and the anticipated launch next year of a blood based test for Down's syndrome. Although success is far from assured, the development of that assay has done much to resurrect the company's prospects.
Sequenom Is Improving Prenatal Screening, in Steps
Article preview reprinted from Start-Up - December 2008
There's been a justifiable buzz around Sequenom Inc.'s prenatal diagnostic technology and the anticipated launch next year of a blood-based test for fetal trisomy 21, or Down's syndrome (the T21 test). Although success is far from assured, the development of that assay has done much to resurrect the company's prospects. And even though it will take time to advance, the platform's evolution provides still another example of a business model based on the development and delivery of a critical, high-value molecular diagnostic test.
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Companies mentioned in this article:
Chinese University of Hong Kong Sequenom Inc. Sequenom Pharmaceuticals
START-UP: No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics. Subscribe to START-UP.
